Reindl M,Waters P .2019 .Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol, 10(2) : 89-102.
Takai Y,Misu T,Kaneko K,Chihara N,Narikawa K,Tsuchida S .2020 .Myelin oligodendrocyte glycoprotein antibodyassociated disease: An immunopathological study. Brain, 10(5) : 1431-46.
Li Y,Liu X,Wang J,Pan C,Z. C .2022 .Clinical features and imaging ndings of myelin oligodendrocyte glycoproteinIgG-associated disorder (MOGAD). Front Aging Neurosci, 850743 : 850743.
Ambrosius W,Michalak S,Kozubski W,Kalinowska A .2020 .Myelin oligodendrocyte glycoprotein antibody-associated disease: Current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci, 10(1) : 100.
de Mol CL,Wong Y,van Pelt ED,Wokke B,Siepman T,Neuteboom RF .2020 .The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler, 10(7) : 806-14.
Nakamura M,Ogawa R,Fujimori J,Uzawa A,Sato Y,Nagashima K .2023 .Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. Mult Scler, 10(4-5) : 530-9.
Leray E,Moreau T,Fromont A,Edan G .2015 .Epidemiology of multiple sclerosis. Rev Neurol, 10(1) : 3-13.
Banwell B,Bennett JL,Marignier R,Kim HJ,Brilot F,Flanagan EP .2023 .Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria. Lancet Neurol, 4422(22) : 00431-8.
Jarius S,Paul F,Aktas O,Asgari N,Dale RC,de Seze J .2018 .MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. J Neuroin, 10(1) : 134.
Abrams BM,Waldman HJ .2008 .Electromyography and Evoked Potentials. Raj's Practical Management of Pain, : 297-321.
Chen C,Liu C,Fang L,Zou Y,Ruan H,Wang Y .2019 .Di erent magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study. J Neurol Sci, 116430 : 116430.
Senanayake B,Jitprapaikulsan J,Aravinthan M,Wijesekera JC,Ranawaka UK,Ri sy MT .2019 .Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. J Neurol Neurosurg Psychiatry, 10(12) : 1381-3.
Chen JJ,Flanagan EP,Bhatti MT,Jitprapaikulsan J,Dubey D,Chiriboga ASSL .2020 .Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology, 10(2) : e111-20.
Chaudhuri J,Biswas T,Ganguly G,Datta S,Pandit A,Biswas A,Ab A .2021 .-associated diseases: An Indian perspective. Acta Neurol Belg, 10(4) : 927-31.
Qayyum F,Sheikh S,Ahmad A,Ahmed T,Awan S .2019 .Anti-MOG antibody associated neurological disorders: A retrospective audit. J Neurol Sci, 10 : 72.
Jarius S,Ruprecht K,Kleiter I,Borisow N,Asgari N,Pitarokoili K .2016 .MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeJ. , 10(1) : 280.
Jarius S,Ruprecht K,Kleiter I,Borisow N,Asgari N,Pitarokoili K .2016 .MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 1: Frequency, syndrome speci city, in uence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroin, 10(1) : 279.